HomeCompareNDBKY vs JNJ

NDBKY vs JNJ: Dividend Comparison 2026

NDBKY yields 6.52% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NDBKY wins by $29117.62M in total portfolio value
10 years
NDBKY
NDBKY
● Live price
6.52%
Share price
$15.83
Annual div
$1.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29117.65M
Annual income
$28,284,835,387.36
Full NDBKY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NDBKY vs JNJ

📍 NDBKY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNDBKYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NDBKY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NDBKY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NDBKY
Annual income on $10K today (after 15% tax)
$554.57/yr
After 10yr DRIP, annual income (after tax)
$24,042,110,079.26/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, NDBKY beats the other by $24,042,106,093.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NDBKY + JNJ for your $10,000?

NDBKY: 50%JNJ: 50%
100% JNJ50/50100% NDBKY
Portfolio after 10yr
$14558.84M
Annual income
$14,142,420,038.38/yr
Blended yield
97.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NDBKY
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
0.2
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NDBKY buys
0
JNJ buys
0
No recent congressional trades found for NDBKY or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNDBKYJNJ
Forward yield6.52%2.13%
Annual dividend / share$1.03$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$29117.65M$30.3K
Annual income after 10y$28,284,835,387.36$4,689.40
Total dividends collected$29060.22M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: NDBKY vs JNJ ($10,000, DRIP)

YearNDBKY PortfolioNDBKY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,005$1,304.88$10,592$272.30+$1.4KNDBKY
2$15,773$2,928.02$11,289$357.73+$4.5KNDBKY
3$24,068$7,190.91$12,123$472.89+$11.9KNDBKY
4$46,263$20,509.47$13,141$629.86+$33.1KNDBKY
5$123,187$73,686.00$14,408$846.81+$108.8KNDBKY
6$498,557$366,746.75$16,021$1,151.60+$482.5KNDBKY
7$3,307,814$2,774,358.16$18,122$1,588.22+$3.29MNDBKY
8$37,945,442$34,406,081.11$20,930$2,228.20+$37.92MNDBKY
9$778,335,925$737,734,301.88$24,792$3,191.91+$778.31MNDBKY
10$29,117,654,827$28,284,835,387.36$30,274$4,689.40+$29117.62MNDBKY

NDBKY vs JNJ: Complete Analysis 2026

NDBKYStock

Nedbank Group Limited, together with its subsidiaries, provides various wholesale and retail banking services in South Africa and internationally. It offers personal banking solutions, including savings deposits and investment accounts; home and personal loans, student loans, vehicle finance products, private wealth finance solutions, overdrafts, short term loans, and credit cards; and investment plans and services, financial, and estate planning services, and wills and trust services, as well as professional banking, wealth management, non-resident and embassy banking, insurance, stock broking, and foreign exchange services. The company also provides business banking services, such as business accounts; call, fixed, and flexi deposits; loans and structured solutions; property, asset, and vehicle finance products; value added services; card and cash solutions; treasury solutions; cash management, electronic banking, and merchant payment and support services; life, asset, income and credit protection, funeral, business cover, liability cover, revenue cover, and owners' insurance products; asset management services; and commodities, equities, fixed income, and structured credit products. In addition, the company offers corporate banking services comprising aircraft, asset based, carbon, export credit, global commodity, infrastructure, energy, telecoms, leveraged, mining, oil and gas, private equity, and public sector finance; payments and receipts, documentary credits and collections, guarantees, and trade finance; structured solutions; corporate lending and advances; custodial services; corporate finance and debt advisory services; beta solutions; and corporate and institutional investments. Further, it provides transactional banking services. The company was formerly known as Nedcor Limited and changed its name to Nedbank Group Limited in 2005. Nedbank Group Limited was founded in 1831 and is headquartered in Sandton, South Africa.

Full NDBKY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NDBKY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NDBKY vs SCHDNDBKY vs JEPINDBKY vs ONDBKY vs KONDBKY vs MAINNDBKY vs ABBVNDBKY vs MRKNDBKY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.